title: Bis-azaaromatic quaternary ammonium salts as ligands for the blood-brain barrier choline transporter.
abstract: A series of bis-azaaromatic quaternary ammonium compounds containing flexible polymethylenic linkers as well as conformationally restricted linkers were evaluated for their affinity for the blood-brain barrier choline transporter (BBB-ChT). The preliminary structure-activity relationships obtained from this study suggest that incorporating a linear, conformationally restricted linker into the molecule improves affinity for the BBB-ChT.
authors.affiliation: Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0082, USA.
authors.forename: Guangrong
authors.initials: G
authors.lastname: Zheng
authors.forename: Zhenfa
authors.initials: Z
authors.lastname: Zhang
authors.forename: Paul R
authors.initials: PR
authors.lastname: Lockman
authors.forename: Werner J
authors.initials: WJ
authors.lastname: Geldenhuys
authors.forename: David D
authors.initials: DD
authors.lastname: Allen
authors.forename: Linda P
authors.initials: LP
authors.lastname: Dwoskin
authors.forename: Peter A
authors.initials: PA
authors.lastname: Crooks
mesh_terms: D000818:Animals; D001812:Blood-Brain Barrier; D008024:Ligands; D026901:Membrane Transport Proteins / Q000378:metabolism*; D000644:Quaternary Ammonium Compounds / Q000378:metabolism*; D012492:Salts; D013329:Structure-Activity Relationship
chemical_list: D008024:Ligands; D026901:Membrane Transport Proteins; D000644:Quaternary Ammonium Compounds; D012492:Salts; C065637:choline transporter
references.citation: Eur J Pharmacol. 2008 Dec 28;601(1-3):103-5
references.pmid: 19000671
references.citation: Br J Pharmacol. 2008 Feb;153(4):792-804
references.pmid: 18059317
references.citation: Biochem Pharmacol. 2009 Oct 1;78(7):889-97
references.pmid: 19631612
references.citation: Nat Rev Drug Discov. 2002 Feb;1(2):131-9
references.pmid: 12120094
references.citation: J Pharmacol Exp Ther. 2008 Jan;324(1):244-50
references.pmid: 17921191
references.citation: J Pharmacol Exp Ther. 2008 Aug;326(2):563-76
references.pmid: 18460644
references.citation: Bioorg Med Chem Lett. 2002 Nov 4;12(21):3067-71
references.pmid: 12372503
references.citation: Am J Physiol. 1984 Sep;247(3 Pt 2):H484-93
references.pmid: 6476141
references.citation: J Neurochem. 2001 Feb;76(4):1032-41
references.pmid: 11181822
references.citation: Biochem Pharmacol. 2009 Oct 1;78(7):732-43
references.pmid: 19523455
references.citation: Nebr Symp Motiv. 2009;55:31-63
references.pmid: 19013938
references.citation: Drug Metab Dispos. 2008 Oct;36(10):2024-9
references.pmid: 18617603
references.citation: Neuropharmacology. 2007 Mar;52(3):755-63
references.pmid: 17097117
references.citation: Neurochem Res. 2004 Dec;29(12):2245-50
references.pmid: 15672546
references.citation: Life Sci. 2003 Aug 15;73(13):1609-15
references.pmid: 12875893
references.citation: Bioorg Med Chem Lett. 2007 Dec 15;17(24):6734-8
references.pmid: 18029180
references.citation: J Pharmacol Exp Ther. 2003 Mar;304(3):1268-74
references.pmid: 12604705
references.citation: Neuropsychopharmacology. 2009 Jan;34(1):244-6
references.pmid: 19079069
references.citation: Neurosci Lett. 1999 Dec 31;277(3):198-202
references.pmid: 10626847
references.citation: Bioorg Med Chem Lett. 2004 Jun 21;14(12):3085-92
references.pmid: 15149650
references.citation: Bioorg Med Chem Lett. 2004 Apr 19;14(8):1869-74
references.pmid: 15050618
references.citation: Psychopharmacology (Berl). 2006 Mar;184(3-4):426-34
references.pmid: 16220336
references.citation: Bioorg Med Chem. 2005 Jul 1;13(13):4253-61
references.pmid: 15878282
references.citation: Drug Dev Ind Pharm. 2002 Aug;28(7):749-71
references.pmid: 12236062
references.citation: Bioorg Med Chem Lett. 2010 Feb 1;20(3):870-7
references.pmid: 20053562